A systematic review of the evidence for the treatment of acute depression in bipolar i disorder

CNS Spectrums

Volumn 18, Issue 4, 2013, Pages 199-208

  Cerullo, Michael A ^a   Strakowski, Stephen M ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Bipolar depression; fMRI; Keywords Bipolar disorder; treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ARMODAFINIL; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; ETIRACETAM; FLUOXETINE PLUS OLANZAPINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM SALT; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADJUVANT THERAPY; AKATHISIA; APPETITE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLEEDING; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INCREASED APPETITE; INSOMNIA; LOW DRUG DOSE; MANIA; METABOLIC SYNDROME X; MONOTHERAPY; MYALGIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; TREATMENT OUTCOME;

EID: 84880557831     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000102     Document Type: Review

References (51)

1. Narrow W, Rae D, Robins L, et al. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002; 59: 115-123.
2. Judd L, Akiskal H. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73: 123-131.
3. Zornberg G, Pope H. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993; 13(6): 397-408.
4. Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilizers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010; 196: 266-273.
5. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011; 129: 14-26.
6. Vieta E, Locklear J, Gunther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol. 2010; 30(5): 579-590.
7. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry. 2009; 194: 4-9.
8. De Fruyt F, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2011; 26(5): 603-617.
9. Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010; 122: 1-9.
10. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010; 124: 228-234.
11. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: an update. J Affect Disord. 2008; 109: 21-34.
12. Dodd BM. Bipolar II disorder: a review. Bipolar Disord. 2005; 7: 11-21.
13. Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011; 72(2): 156-167.
14. Gijsman H, Geddes J, Rendell J, Nolen W, Goodwin G. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004; 161(9): 1537-1547.
15. Spanemberg L, Massuda R, Lovato L, et al. Pharmacological treatment of bipolar depression: qualitative systematic review of double-blind randomized clinical trials. Psychiatr Q. 2012; 83: 161-175.
16. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7): 1351-1360.
17. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression. J Clin Psychopharmacol. 2006; 26(6): 600-609.
18. McElroy S, Weisler R, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71(2): 163-174.
19. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010; 121: 106-115.
20. Young AH, FRCPsych McElroy SL, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010; 71(2): 150-162.
21. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60: 1079-1088.
22. Tohen M, McDonnell DP, Case M, et al. Randomized, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. In press. DOI: 10.1192/bjp.bp.112.108357.
23. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008; 28(1): 13-20.
24. Lombardo L, Sachs G, Kolluri S, Kremer C, Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression. J Clin Psychopharmacol. 2012; 32(4): 470-478.
25. Sachs GS, Ice KS, Chappell PB. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(10): 1413-1422.
26. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008; 10: 323-333.
27. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I disorder. J Clin Psychiatry. 1999; 60(2): 79-88.
28. van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(2): 223-231.
29. Brown EB, McElroy SL, Keck PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 206; 67: 1025-1033.
30. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005; 85: 259-266.
31. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007; 68(12): 1840-1844.
32. Muzina DJ, Gao K, Kemp DE. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-nai've bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011; 72(6): 813-819.
33. Baron MB, Gershon ES, Rudy V, et al. Lithium carbonate response in depression. Arch Gen Psychiatry. 1975; 32: 1107-1111.
34. Goodwin FK, Murphy DL, BunneyWE. Lithium-carbonate treatment in depression and mania. Arch Gen Psychiatry. 1969; 21: 486-496.
35. Noyes R, Dempsey GM, Blum A, Cavanaugh GL. Lithium treatment of depression. Compr Psychiatry. 1974; 15(3): 187-193.
36. Stokes PE, Stoll PM, Shamoian CA, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet. 1971; 1: 1319-1325.
37. Goodwin FK, Murphy DL, Dunner DL, Bunney WE. Lithium response in unipolar versus bipolar depression. Am J Psychiatry. 1972; 129(1): 76-79.
38. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989; 4: 313-322
39. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001; 158(6): 906-912.
40. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356(17): 1711-1722.
41. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010; 71(10): 1363-1370.
42. Saricicek A, Maloney K, Muralidharan A, et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(6): 744-750.
43. Ghaemi SN, Goodwin FK. Antidepressants for bipolar depression. Am J Psychiatry. 2005; 162(8): 1545-1546.
44. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003; 5: 407-420.
45. Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive metaanalytic review. Acta Psychiatr Scand. 2010; 121: 404-414.
46. Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008; 118: 337-346.
47. Frye MA, Grunze H, Suppes T, et al. A placebocontrolled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007; 164: 1242-1249.
48. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder. Arch Gen Psychiatry. 1999; 56: 407-412.
49. Keck PE, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyleicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006; 60: 1020-1022.
50. Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded randomized study. J Clin Psychiatry. 2009; 70(4): 450-457.
51. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a systematic treatment enhancement program for bipolar disorder (STEP-BP) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010; 71(4): 372-380.